
ASH22
Most Read


Virtual Event: “ASH Recap, Live!” 2022

STAT Plus: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

STAT Plus: Affimed’s natural killer cell therapy has murky path forward despite encouraging results

STAT Plus: Novartis develops CAR-T therapy that can be made in a fraction of the standard time

STAT Plus: Argenx antibody drug benefits patients with platelet-destroying autoimmune disorder

STAT Plus: ‘We’ve got a new target’: Bispecific antibody for multiple myeloma succeeds in mid-stage trial
